Form 4: Raymond Debbane Reports Changes in Beneficial Ownership of Lexicon Pharmaceuticals
SEC Form 4
Raymond Debbane, a director at Lexicon Pharmaceuticals, reports a transaction involving restricted stock units and common stock.
Summary
- On April 28, 2024, Raymond Debbane, a director of Lexicon Pharmaceuticals, engaged in transactions involving the company's securities.
- Debbane acquired 8,032 shares of common stock upon the vesting of restricted stock units.
- Following the transaction, Debbane directly owns 1,348,879 shares of common stock and indirectly owns 5,451,204 shares through Invus US Partners LLC.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing changes in beneficial ownership. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects a change in the director's holdings.
Key Dates
| Date | Description |
|---|---|
| 04/28/2024 | Date of transaction involving restricted stock units and common stock. |
| 04/29/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.